Revolution Medicines (RVMD) Receivables (2020 - 2023)

Revolution Medicines' Receivables history runs 4 years deep, the most recent figure standing at $1.3 million for Q4 2023.

• On a quarterly basis, Receivables fell 73.16% year-over-year to $1.3 million in Q4 2023; TTM through Dec 2023 was $1.3 million, a 73.16% decrease from a year earlier, with the FY2023 full-year figure at $1.3 million, down 73.16% from the prior year.
• Receivables climbed to $1.3 million in Q4 2023 per RVMD's latest filing, from $309000.0 in the prior quarter.
• Across five years, Receivables topped out at $12.8 million in Q4 2020 and bottomed at $309000.0 in Q3 2023.
• The 4-year median for Receivables is $5.4 million (2022), against an average of $5.3 million.
• Across the five-year window, Receivables declined 13.83% in 2022 and plunged 93.74% in 2023, its largest moves.
• Year by year, Receivables stood at $12.8 million in 2020, then slumped by 53.63% to $5.9 million in 2021, then dropped by 21.18% to $4.7 million in 2022, then plunged by 73.16% to $1.3 million in 2023.
• Per Business Quant, the three latest RVMD Receivables figures stand at $1.3 million (Q4 2023), $309000.0 (Q3 2023), and $2.5 million (Q2 2023).